Potential Public Health Impact of New Tuberculosis Vaccines
Elad Ziv*, Charles L. Daley*†, and Sally Blower‡
Author affiliations: *University of California—San Francisco, San Francisco, California, USA; †San Francisco General Hospital, San Francisco, California, USA; ‡David Geffen School of Medicine at UCLA, Los Angeles California, USA
Figure 4. Unadjusted predicted data are plotted; red points represent postexposure vaccines, black points represent preexposure vaccines. A) Cumulative percentage of tuberculosis (TB) cases prevented. B) Cumulative percentage of TB cases prevented. C) Cumulative percentage of TB cases prevented. Cases prevented after 20 years of vaccination are shown as a function of vaccination coverage rates, duration of vaccine-induced immunity, or vaccine efficacy.
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.